Clinical trial
A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)
NCT07791043 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 31, 2026
- Completion date
- January 14, 2030
- Enrollment
- 274 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.